SOBERANA 02抗SARS-CoV-2疫苗在同源或异源方案中的安全性和免疫原性:开放标签I期和IIa期临床试验
SOBERANA 02是以SARS-CoV-2重组RBD偶联破伤风类毒素(TT)的COVID-19疫苗,SOBERANA Plus抗原为二聚体RBD。开放标签序贯适应性I期在40名19-59岁受试者中比较15或25 μg RBD(偶联20 μg TT)两剂方案,IIa期纳入100名19-80岁志愿者接种两剂SOBERANA 02-25 μg,半数受试者第三剂接受同源SOBERANA 02、半数接受异源SOBERANA Plus。最常见不良事件为局部疼痛,其他不良事件频率≤5%,未报告严重相关不良事件;异源三剂方案免疫应答最高。
要点
- 最常见不良事件为局部疼痛,其他不良事件频率≤5%,未报告严重相关不良事件。
- IIa期确认60-80岁受试者安全性,SOBERANA 02-25 μg免疫原性在该年龄组亦获确认。
- 异源三剂方案(第三剂SOBERANA Plus)显示更高的免疫学应答。
核心结论
- SOBERANA 02在19-80岁人群中安全且有免疫原性,可诱生中和抗体和特异性T细胞应答。
- 异源三剂方案获得最高的免疫应答。
研究设计与样本
- 开放标签、序贯、适应性I期临床试验在40名19-59岁受试者中评估两种配方(15或25 μg RBD偶联20 μg TT)的SOBERANA 02安全性和免疫原性。
- 开放标签IIa期临床试验纳入100名19-80岁志愿者,接种两剂SOBERANA 02-25 μg。
- 两项试验中半数志愿者第三剂接种对应的SOBERANA 02(同源),半数接种异源SOBERANA Plus。
- 主要结局为安全性,次要结局为通过抗RBD IgG ELISA、RBD:hACE2分子中和试验、活病毒中和试验和特异性T细胞应答评估的免疫原性。
主要发现
- 最常见不良事件为局部疼痛,其他不良事件频率≤5%,未报告严重相关不良事件。
- IIa期确认60-80岁受试者安全性。
- I期中SOBERANA 02-25 μg诱导的免疫应答高于SOBERANA 02-15 μg,并推进至IIa期。
- IIa期结果确认SOBERANA 02-25 μg即使在60-80岁人群中也有免疫原性。
- 两剂SOBERANA 02-25 μg诱导的免疫应答与古巴康复者血清面板相似,同源和异源第三剂后应答更高,异源方案显示更高的免疫学应答。
关键数值与推荐
- I期两种配方:15或25 μg RBD偶联20 μg TT。
- IIa期使用SOBERANA 02-25 μg两剂方案。
- 第三剂为同源SOBERANA 02或异源SOBERANA Plus。
- 抗RBD IgG对delta变异株的中和较D614G降低2.5倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we report safety and immunogenicity from phase I and IIa clinical trials using two-doses of SOBERANA 02 and three-doses (homologous) or heterologous (with SOBERANA Plus) protocols. METHOD: We performed an open-label, sequential and adaptive phase I to evaluate safety and explore the immunogenicity of SOBERANA 02 in two formulations (15 or 25 μg RBD-conjugated to 20 μg of TT) in 40 subjects, 19-59-years-old. Phase IIa was open-label including 100 volunteers 19-80-years, receiving two doses of SOBERANA 02-25 μg. In both trials, half of volunteers were selected to receive a third dose of the corresponding SOBERANA 02 and half received a heterologous dose of SOBERANA Plus. Primary outcome was safety. The secondary outcome was immunogenicity evaluated by anti-RBD IgG ELISA, molecular neutralization of RBD:hACE2 interaction, live-virus-neutralization and specific T-cells response. RESULTS: The most frequent adverse event (AE) was local pain, other AEs had frequencies ≤ 5%. No serious related-AEs were reported. Phase IIa confirmed the safety in 60 to 80-years-old subjects. In phase-I SOBERANA 02-25 µg elicited higher immune response than SOBERANA 02-15 µg and progressed to phase IIa. Phase IIa results confirmed the immunogenicity of SOBERANA 02-25 µg even in 60-80-years. Two doses of SOBERANA02-25 µg elicited an immune response similar to that of the Cuban Convalescent Serum Panel and it was higher after the homologous and heterologous third doses. The heterologous scheme showed a higher immunological response. Anti-RBD IgG neutralized the delta variant in molecular assay, with a 2.5-fold reduction compared to D614G neutralization. CONCLUSIONS: SOBERANA 02 was safe and immunogenic in persons aged 19-80 years, eliciting neutralizing antibodies and specific T-cell response. Highest immune responses were obtained in the heterologous three doses protocol. TRIAL REGISTRY: https://rpcec.sld.cu/trials/RPCEC00000340, https://rpcec.sld.cu/trials/RPCEC00000347.
引用
- Eugenia-Toledo-Romaní M, Verdecia-Sánchez L, Rodríguez-González M, et al. Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials. Vaccine. 2022. PMID: 35691871. doi:10.1016/j.vaccine.2022.05.082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。